Alejandro Brun Editor Vaccine Technologies for Veterinary Viral Diseases Methods and Protocols M ETHODS in MOLECULAR BIOLOGY

Total Page:16

File Type:pdf, Size:1020Kb

Alejandro Brun Editor Vaccine Technologies for Veterinary Viral Diseases Methods and Protocols M ETHODS in MOLECULAR BIOLOGY Methods in Molecular Biology 1349 Alejandro Brun Editor Vaccine Technologies for Veterinary Viral Diseases Methods and Protocols M ETHODS IN MOLECULAR BIOLOGY Series Editor John M. Walker School of Life and Medical Sciences University of Hertfordshire Hat fi eld, Hertfordshire, AL10 9AB, UK For further volumes: http://www.springer.com/series/7651 Vaccine Technologies for Veterinary Viral Diseases Methods and Protocols Edited by Alejandro Brun CISA-INIA, Valdeolmos, Madrid, Spain Editor Alejandro Brun CISA-INIA Valdeolmos , Madrid , Spain ISSN 1064-3745 ISSN 1940-6029 (electronic) Methods in Molecular Biology ISBN 978-1-4939-3007-4 ISBN 978-1-4939-3008-1 (eBook) DOI 10.1007/978-1-4939-3008-1 Library of Congress Control Number: 2015949635 Springer New York Heidelberg Dordrecht London © Springer Science+Business Media New York 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specifi c statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper Humana Press is a brand of Springer Springer Science+Business Media LLC New York is part of Springer Science+Business Media (www.springer.com) Pref ace A great amount of knowledge has been generated in recent years on veterinary vaccine technologies, so presently many different antigen delivery systems are available for vaccine research, in particular against viral diseases. This book was intended to review most popular antigen production and delivery strategies that have been tested in veterinary species. Viral vectors as well as genetic and protein subunit vaccines or large-scale protein production systems are considered among the different chapters of the book. Our aim has been to facilitate the access to real and well-established protocols to those beginning in this interest- ing and laborious fi eld as well as to provide basic knowledge when attempting a novel vac- cine design or platform. This book, in addition, will provide an updated view of most options available when vaccine development is considered. In spite of the number of alter- natives available for vaccine design, few of them often reach market and commercialization, but, nonetheless, the data obtained along experimental trials contribute to the exploration and understanding of the immune mechanisms and immune correlates relevant in protec- tion among different animal species. Therefore this book also could be of help to those interested in basic and applied immunology, since these technologies represent interesting tools to induce or modulate different host immune mechanisms. Valdeolmos, Madrid, Spain Alejandro Brun v Contents Preface. v Contributors . ix 1 Vaccines and Vaccination for Veterinary Viral Diseases: A General Overview . 1 Alejandro Brun 2 Using IC-Tagging Methodology for Production and Purification of Epitope-Loaded Protein Microspheres for Vaccination . 25 Natalia Barreiro- Piñeiro , Rebeca Menaya-Vargas , Alberto Brandariz-Núñez , Iria Otero- Romero , Irene Lostalé-Seijo , Javier Benavente , and José M. Martínez-Costas 3 Plant-Based Vaccine Antigen Production. 35 Hoang Trong Phan and Udo Conrad 4 DNA Vaccines: Experiences in the Swine Model . 49 Francesc Accensi , Fernando Rodríguez , and Paula L. Monteagudo 5 Novel Adjuvants and Immunomodulators for Veterinary Vaccines . 63 Peter M.H. Heegaard , Yongxiang Fang , and Gregers Jungersen 6 Polymerase Mechanism-Based Method of Viral Attenuation . 83 Cheri A. Lee , Avery August , Jamie J. Arnold , and Craig E. Cameron 7 BacMam Platform for Vaccine Antigen Delivery . 105 Günther M. Keil , Reiko Pollin , Claudia Müller , Katrin Giesow , and Horst Schirrmeier 8 Laboratory-Scale Production of Replication-Deficient Adenovirus Vectored Vaccines . 121 Susan J. Morris , Alison V. Turner , Nicola Green , and George M. Warimwe 9 Generation of Recombinant Modified Vaccinia Virus Ankara Encoding VP2, NS1, and VP7 Proteins of Bluetongue Virus. 137 Alejandro Marín- López and Javier Ortego 10 Generation of Recombinant Capripoxvirus Vectors for Vaccines and Gene Knockout Function Studies . 151 Hani Boshra , Jingxin Cao , and Shawn Babiuk 11 Recombinant Swinepox Virus for Veterinary Vaccine Development . 163 Hong-Jie Fan and Hui-Xing Lin 12 Generation and Selection of Orf Virus (ORFV) Recombinants . 177 Hanns-Joachim Rziha , Jörg Rohde , and Ralf Amann vii viii Contents 13 Polycistronic Herpesvirus Amplicon Vectors for Veterinary Vaccine Development . 201 Anita Felicitas Meier , Andrea Sara Laimbacher , and Mathias Ackermann 14 Construction and Application of Newcastle Disease Virus- Based Vector Vaccines . 225 Paul J. Wichgers Schreur 15 Chimeric Pestivirus Experimental Vaccines . 239 Ilona Reimann , Sandra Blome , and Martin Beer 16 Analysis of the Cellular Immune Responses to Vaccines . 247 Nicholas Svitek , Evans L. N. Taracha , Rosemary Saya , Elias Awino , Vishvanath Nene , and Lucilla Steinaa Index . 263 Contributors FRANCESC ACCENSI • Centre de Recerca en Sanitat Animal (CReSA) , Bellaterra , Barcelona , Spain ; Departament de Sanitat i d’Anatomia Animals, Universitat Autònoma de Barcelona (UAB) , Bellaterra, Barcelona , Spain MATHIAS ACKERMANN • Vetsuisse Faculty, Institute of Virology , University of Zurich , Zurich , Switzerland RALF AMANN • Institute of Immunology , Friedrich-Loeffl er-Institute , Greifswald, Island of Riems , Germany; Department of Immunology, Interfaculty Institute of Cell Biology, Eberhard Karls Universität, Tübingen, Germany JAMIE J. ARNOLD • Department of Biochemistry and Molecular Biology, The Pennsylvania State University , University Park , PA , USA AVERY AUGUST • Department of Microbiology and Immunology, College of Veterinary Medicine , Cornell University , Ithaca , NY , USA ELIAS AWINO • Vaccine Biosciences, International Livestock Research Institute , Nairobi , Kenya SHAWN BABIUK • Canadian Food Inspection Agency , Winnipeg , MB , Canada NATALIA BARREIRO-PIÑEIRO • Department of Biochemistry and Molecular Biology, Centro Singular de Investigación en Química Biológica y Materiales Moleculares (CIQUS) , University of Santiago de Compostela , Santiago de Compostela , Spain MARTIN BEER • Institute of Diagnostic Virology , Friedrich-Loeffl er-Institut , Greifswald, Insel Riems , Germany JAVIER BENAVENTE • Department of Biochemistry and Molecular Biology, Centro Singular de Investigación en Química Biológica y Materiales Moleculares (CIQUS) , University of Santiago de Compostela , Santiago de Compostela , Spain SANDRA BLOME • Institute of Diagnostic Virology , Friedrich-Loeffl er-Institut , Greifswald, Insel Riems , Germany HANI BOSHRA • Canadian Food Inspection Agency , Winnipeg , MB , Canada ALBERTO BRANDARIZ-NÚÑEZ • Department of Biochemistry and Molecular Biology, Centro Singular de Investigación en Química Biológica y Materiales Moleculares (CIQUS) , University of Santiago de Compostela , Santiago de Compostela , Spain ; Department of Biochemistry, Center for Biophysics and Computational Biology, University of Illinois at Urbana-Champaign , Urbana , IL , USA ALEJANDRO BRUN • Centro de Investigación en Sanidad Animal (CISA) , Instituto Nacional de Investigación y Tecnología Agraria y Almentaria (INIA) , Valdeolmos , Madrid , Spain CRAIG E. CAMERON • Department of Biochemistry and Molecular Biology, The Pennsylvania State University , University Park , PA , USA JINXING CAO • Public Health Agency of Canada , Winnipeg , MB , Canada UDO CONRAD • Department of Molecular Genetics , Leibniz Institute of Plant Genetics and Crop Plant Research (IPK) , Gatersleben , Germany ix x Contributors HONG-JIE FAN • College of Veterinary Medicine , Nanjing Agricultural University , Nanjing , China YONGXIANG FANG • Section for Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark , Frederiksberg C , Denmark ; State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Public Health of Ministry of Agriculture , Lanzhou Veterinary Research Institute, CAAS , Lanzhou , China KATRIN GIESOW • Institut für Molekulare Virologie und Zellbiologie und Institut für Virusdiagnostik , Friedrich-Loeffl er-Institut , Greifswald, Insel Riems, Germany; Institut für VirusdiagnostikFriedrich-Loeffl er-Institut, Greifswald, Insel Riems, Germany NICOLA GREEN • The Clinical Biomanufacturing Facility , University of Oxford , Oxford , UK PETER M. H. HEEGAARD • Section for Immunology and Vaccinology, National Veterinary Institute , Technical University of Denmark , Frederiksberg C , Denmark GREGERS JUNGERSEN • Section for Immunology and Vaccinology, National Veterinary Institute , Technical University of Denmark , Frederiksberg
Recommended publications
  • Outbreak of Sheeppox in Farmed Sheep in Kyrgystan: Histological, Eletron Micro- Scopical and Molecular Characterization
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2016 Outbreak of sheeppox in farmed sheep in Kyrgystan: Histological, eletron microscopical and molecular characterization Aldaiarov, N ; Stahel, A ; Nufer, L ; Jumakanova, Z ; Tulobaev, A ; Ruetten, M Abstract: INTRODUCTION On a farm in the Kyrgyz Republic, several dead sheep were found without any history of illness. The sheep showed several ulcerations on lips and bare-skinned areas. At necropsy the lungs showed multiple firm nodules, which were defined as pox nodules histologically. Intherumen hyperkeratotic plaques were visible. With electron microscopy pox viral particles were detected and con- firmed with q PCR as Capripoxviruses. Although all members of the Capripoxvirus genus are eradicated in western countries, this study should remind us of the classical lesions observed in poxvirus infections. DOI: https://doi.org/10.17236/sat00076 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-126889 Journal Article Published Version Originally published at: Aldaiarov, N; Stahel, A; Nufer, L; Jumakanova, Z; Tulobaev, A; Ruetten, M (2016). Outbreak of sheep- pox in farmed sheep in Kyrgystan: Histological, eletron microscopical and molecular characterization. Schweizer Archiv für Tierheilkunde, 158(7):529-532. DOI: https://doi.org/10.17236/sat00076 Fallberichte | Case reports Outbreak of sheeppox in farmed sheep in Kyrgystan: Histological, eletron micro- scopical
    [Show full text]
  • Photoaging & Skin Damage
    Use_for_Revised_OFC_Only_2006_PhotoagingSkinDamage 5/21/13 9:11 AM Page 2 PEORIA (309) 674-7546 MORTON (309) 263-7546 GALESBURG (309) 344-5777 PERU (815) 224-7400 NORMAL (309) 268-9980 CLINTON, IA (563) 242-3571 DAVENPORT, IA (563) 344-7546 SoderstromSkinInstitute.comsoderstromskininstitute.com FROMFrom YOUR Your DERMATOLOGISTDermatologist [email protected]@skinnews.com PHOTOAGING & SKIN DAMAGE Before You Worship The Sun Who’s At Risk? Today, many researchers and dermatologists Skin types that burn easily and tan rarely are believe that wrinkling and aging changes of the skin much more susceptible to the ravages of the sun on the are much more related to sun damage than to age! skin than are those that tan easily, rather than burn. Many of the signs of skin damage from the sun are Light complected, blue-eyed, red-haired people such as pictured on these pages. The decrease in the ozone Swedish, Irish, and English, are usually more suscep- layer, increasing the sun’s intensity, and the increasing tible to photo damage, and their skin shows the signs sun exposure among our population – through work, of photo damage earlier in life and in a more pro- sports, sunbathing and tanning parlors – have taken a nounced manner. Dark complexions give more protec- tremendous toll on our skin. Sun damage to the skin tion from light and the sun. ranks with other serious health dangers of smoking, alcohol, and increased cholesterol, and is being seen in younger and younger people. NO TAN IS A SAFE TAN! Table of Contents Sun Damage .............................................Pg. 1 Skin Cancer..........................................Pgs. 2-3 Mohs Micrographic Surgery ......................Pg.
    [Show full text]
  • Glycolic Acid
    Glycolic Acid Pharmacy Compounding Advisory Committee Meeting November 3, 2016 Jane Liedtka, MD Clinical Reviewer Division of Dermatology and Dental Products, Office of Drug Evaluation III Glycolic Acid Review Team Jane Liedtka, MD, Clinical Reviewer, DDDP, ODE3 Ben Zhang, PhD, Chemistry Reviewer, OPQ Jianyong Wang, PhD, Pharmacology/Toxicology Reviewer, DDDP, ODE3 Doanh Tran, PhD., Clinical Pharmacology Team Leader, DCP3, OCP www.fda.gov 2 Nomination • Glycolic acid, 0.08% to 70%, has been nominated for inclusion on the list of bulk drug substances for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for topical use in the treatment of hyperpigmentation disorders and photodamaged skin www.fda.gov 3 Background • Glycolic acid is currently available in cosmetic formulations (creams, pads, and lotions) and present as excipient in some topical drug products www.fda.gov 4 Regulatory Definitions: Drugs and Cosmetics • Whether a product is a cosmetic or a drug under the law is determined by a product's intended use; different laws and regulations apply to each type of product • A drug is an article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or an article (other than food) that is intended to affect the structure or function of the body • A cosmetic is an article (other than soap) intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering appearance – Regulated by CFSAN – No premarket approval of products or ingredients (except color additives) www.fda.gov 5 Cosmetic and Drug Uses of Topical Acids • Topical Acids cause exfoliation, or shedding of the skin surface.
    [Show full text]
  • Acne Treatment: Easy Ways Hospital Family Medicine Residency Program, French Camp, Calif to Improve Your Care [email protected]
    CASE c Tam T. Nguyen, MD San Joaquin General Acne treatment: Easy ways Hospital Family Medicine Residency Program, French Camp, Calif to improve your care [email protected] The author reported no For patients of any age, facial lesions can cause potential conflict of interest relevant to this article. considerable embarrassment and distress. Read on to discover what key component of acne treatment you should be using (but probably aren’t) and which dosage you can safely lower. c Practice CASE Janis S, an otherwise healthy 19-year-old, is in your recommendations office, seeking treatment for acne. She reports she has tried various over-the-counter (oTc) creams in recent months, but › Use a classification system, has seen little improvement. The acne first appeared about such as that of the American 5 years ago, and her pediatrician prescribed topical adapalene Academy of Dermatol- and doxycycline. The treatment helped, but she says her face ogy, to assess the severity never fully cleared up; over the past year, the acne has gotten of acne vulgaris. A worse. › Treat inflamma- on examination, you find several nodules and comedones tory lesions aggressively on the patient’s face, chest, and back. ms. S confides in you to prevent scarring. A that the acne—particularly on her face—kept her from going › When isotretinoin is to the senior prom. indicated, consider prescrib- ing a lower dosage (but ore than 80% of adolescents and adults develop longer duration) than the acne vulgaris at some point in their lives, and in traditional regimen. B at least 15% to 20% of cases, the acne is moderate M1 Strength of recommendation (SOR) to severe.
    [Show full text]
  • PDO Thread Lift and Smoothing
    PDO Thread Li and Smoothing Pre-Care and Post-Care Instrucons Pre-Care Instrucons 2 WEEKS BEFORE: ● Avoid taking (unless medically necessary) aspirin, non-steroidal an-inflammatory medicaons such as ibuprofen, Aleve, Advil, Motrin or supplements such as St. John’s Wort, Vitamin E, Fish oil/Omega 3/Flax Seed oil or Melatonin. These agents may increase bruising and bleeding risk. Tylenol is acceptable. Please let Renew Med Spa know if you are on any medicaon, such as blood thinners, that may increase your risk of bruising and/or bleeding. 1 WEEK BEFORE: ● Avoid any topical skincare products that may irritate your skin such as glycolic acid, salicylic acid or renoic (renols) acids. ● If you have any recent skin injecon, acve acne or cold sore in the treatment area, please call our office immediately to reschedule your appointment. 1 DAY BEFORE: ● Oral Arnica should be taken to minimize risk of swelling and bruising. Take Arnica the day before your treatment. ● Please nofy Renew Med Spa or our staff if you have a history of more than 3 facial cold sores a year, as there is a risk that this procedure could cause a recurrence. You can take Valtrex, 2 grams the night before your procedure and another 2 grams 12 hours aer the procedure to prevent cold sores recurrence. DAY OF PROCEDURE: ● Local numbing medicaon will be used to maximize your comfort during the procedure. Most paents report a mild to moderate snging sensaon with numbing injecons. It is important to discuss any sensivity or allergy to Lidocaine, Novocaine or Epinephrine with your provider prior to treatment.
    [Show full text]
  • Experimental Infection and Genetic Characterization of Two Different
    viruses Article Experimental Infection and Genetic Characterization of Two Different Capripox Virus Isolates in Small Ruminants Janika Wolff , Jacqueline King, Tom Moritz, Anne Pohlmann , Donata Hoffmann , Martin Beer and Bernd Hoffmann * Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Südufer 10, D-17493 Greifswald-Insel Riems, Germany; janika.wolff@fli.de (J.W.); jacqueline.king@fli.de (J.K.); [email protected] (T.M.); anne.pohlmann@fli.de (A.P.); donata.hoffmann@fli.de (D.H.); martin.beer@fli.de (M.B.) * Correspondence: Bernd.Hoffmann@fli.de; Tel.: +49-3835-17-1506 Received: 8 September 2020; Accepted: 26 September 2020; Published: 28 September 2020 Abstract: Capripox viruses, with their members “lumpy skin disease virus (LSDV)”, “goatpox virus (GTPV)” and “sheeppox virus (SPPV)”, are described as the most serious pox diseases of production animals. A GTPV isolate and a SPPV isolate were sequenced in a combined approach using nanopore MinION sequencing to obtain long reads and Illumina high throughput sequencing for short precise reads to gain full-length high-quality genome sequences. Concomitantly, sheep and goats were inoculated with SPPV and GTPV strains, respectively. During the animal trial, varying infection routes were compared: a combined intravenous and subcutaneous infection, an only intranasal infection, and the contact infection between naïve and inoculated animals. Sheep inoculated with SPPV showed no clinical signs, only a very small number of genome-positive samples and a low-level antibody reaction. In contrast, all GTPV inoculated or in-contact goats developed severe clinical signs with high viral genome loads observed in all tested matrices.
    [Show full text]
  • Inside This Issue
    Volume 5 | Issue 1 | SkinCare Physicians | 2008 Edition 1244 Boylston Street, Chestnut Hill, MA 02467 | Phone: (617) 731-1600 | Fax: (617) 731-1601 SKINCARE PRESCRIPTION ARRIVES ! After years of exhaustive research and development, on the market, it can be confusing. To simplify SkinCare Physicians is proud to introduce our the skin care process, we have chosen the most new proprietary line of products, SKINCARE innovative and important ingredients available to PRESCRIPTION. With over 100 years of combined create a line of 8 products that our patients can use experience and expertise in skin care, the daily to care for their skin. dermatologists at SkinCare Physicians are uniquely positioned to develop this innovative product line. Unlike all the other products out there, SKINCARE The 8 products include: PRESCRIPTION is different. • Cleanser • Exfoliator The concept behind SKINCARE PRESCRIPTION is • Day Anti-Aging Moisturizer AHA with SPF 15 simple: provide a small group of carefully chosen • Night Anti-Aging Moisturizer with Retinol products that actually improve your skin, and at a • Anti-Aging Eye Cream reasonable price. Most patients use many different • Intensive Anti-Wrinkle Moisturizer (with the products, are never sure just which ones to use SkinCare Physicians special formula) when, and pay too much for them. Every day patients • Age Prevention Vitamin C Serum ask us about the products they should use to keep • Age Reversal Glycolic Acid Serum 10% their skin healthy and young looking, and because there are so many different products to choose from ( continued on page 2 ) YOUTH IN A SYRINGE: THE NEW WAY TO GET DRAMATIC RESULTS WITH FILLERS AND BOTOX INSIDE THIS ISSUE: While it may sound too good to be true, it has never lines between the eyes by combining Restylane been easier to achieve extraordinary results that can or Juvederm with Botox, creating improvement make you look younger in minutes.
    [Show full text]
  • National Program Assessment, Animal Health: 2000-2004
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Department of Agriculture: Agricultural Publications from USDA-ARS / UNL Faculty Research Service, Lincoln, Nebraska 10-5-2004 National Program Assessment, Animal Health: 2000-2004 Cyril G. Gay United States Department of Agriculture, Agricultural Research Service, National Program Staff, [email protected] Follow this and additional works at: https://digitalcommons.unl.edu/usdaarsfacpub Part of the Agriculture Commons, Animal Sciences Commons, and the Animal Studies Commons Gay, Cyril G., "National Program Assessment, Animal Health: 2000-2004" (2004). Publications from USDA- ARS / UNL Faculty. 1529. https://digitalcommons.unl.edu/usdaarsfacpub/1529 This Article is brought to you for free and open access by the U.S. Department of Agriculture: Agricultural Research Service, Lincoln, Nebraska at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Publications from USDA-ARS / UNL Faculty by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. U.S. government work. Not subject to copyright. National Program Assessment Animal Health 2000-2004 National Program Assessments are conducted every five-years through the organization of one or more workshop. Workshops allow the Agricultural Research Service (ARS) to periodically update the vision and rationale of each National Program and assess the relevancy, effectiveness, and responsiveness of ARS research. The National Program Staff (NPS) at ARS organizes National Program Workshops to facilitate the review and simultaneously provide an opportunity for customers, stakeholders, and partners to assess the progress made through the National Program and provide input for future modifications to the National Program or the National Program’s research agenda.
    [Show full text]
  • APPENDIX G Acid Dissociation Constants
    harxxxxx_App-G.qxd 3/8/10 1:34 PM Page AP11 APPENDIX G Acid Dissociation Constants §␮ ϭ 0.1 M 0 ؍ (Ionic strength (␮ † ‡ † Name Structure* pKa Ka pKa ϫ Ϫ5 Acetic acid CH3CO2H 4.756 1.75 10 4.56 (ethanoic acid) N ϩ H3 ϫ Ϫ3 Alanine CHCH3 2.344 (CO2H) 4.53 10 2.33 ϫ Ϫ10 9.868 (NH3) 1.36 10 9.71 CO2H ϩ Ϫ5 Aminobenzene NH3 4.601 2.51 ϫ 10 4.64 (aniline) ϪO SNϩ Ϫ4 4-Aminobenzenesulfonic acid 3 H3 3.232 5.86 ϫ 10 3.01 (sulfanilic acid) ϩ NH3 ϫ Ϫ3 2-Aminobenzoic acid 2.08 (CO2H) 8.3 10 2.01 ϫ Ϫ5 (anthranilic acid) 4.96 (NH3) 1.10 10 4.78 CO2H ϩ 2-Aminoethanethiol HSCH2CH2NH3 —— 8.21 (SH) (2-mercaptoethylamine) —— 10.73 (NH3) ϩ ϫ Ϫ10 2-Aminoethanol HOCH2CH2NH3 9.498 3.18 10 9.52 (ethanolamine) O H ϫ Ϫ5 4.70 (NH3) (20°) 2.0 10 4.74 2-Aminophenol Ϫ 9.97 (OH) (20°) 1.05 ϫ 10 10 9.87 ϩ NH3 ϩ ϫ Ϫ10 Ammonia NH4 9.245 5.69 10 9.26 N ϩ H3 N ϩ H2 ϫ Ϫ2 1.823 (CO2H) 1.50 10 2.03 CHCH CH CH NHC ϫ Ϫ9 Arginine 2 2 2 8.991 (NH3) 1.02 10 9.00 NH —— (NH2) —— (12.1) CO2H 2 O Ϫ 2.24 5.8 ϫ 10 3 2.15 Ϫ Arsenic acid HO As OH 6.96 1.10 ϫ 10 7 6.65 Ϫ (hydrogen arsenate) (11.50) 3.2 ϫ 10 12 (11.18) OH ϫ Ϫ10 Arsenious acid As(OH)3 9.29 5.1 10 9.14 (hydrogen arsenite) N ϩ O H3 Asparagine CHCH2CNH2 —— —— 2.16 (CO2H) —— —— 8.73 (NH3) CO2H *Each acid is written in its protonated form.
    [Show full text]
  • WO 2018/227293 Al 20 December 2018 (20.12.2018) W ! P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/227293 Al 20 December 2018 (20.12.2018) W ! P O PCT (51) International Patent Classification: c/o Jack Bell Research Centre, 2660 Oak Street, Vancouver, A61K 47/30 (2006.01) C08G 63/08 (2006.01) British Columbia V6H 3Z6 (CA). A61K 47/10 (2017.01) C08G 65/28 (2006.01) (74) Agent: MACINS, Andris; Unit 203A - 116 Geary Avenue, A61K 47/34 (2017.01) Toronto, Ontario M6H 4H1 (CA). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/CA20 18/0507 14 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 13 June 2018 (13.06.2018) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (30) Priority Data: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/5 18,800 13 June 2017 (13.06.2017) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (71) Applicant: THE UNIVERSITY OF BRITISH COLUM¬ TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Diagnosis and Treatment of Orf
    Vet Times The website for the veterinary profession https://www.vettimes.co.uk Diagnosis and treatment of orf Author : Graham Duncanson Categories : Farm animal, Vets Date : March 3, 2008 When I used to do a meat inspection for an hour each week, I came across a case of orf in one of the slaughtermen. The lesion was on the back of his hand. The GP thought it was an abscess and lanced the pustule. I was certain it was orf and got some pus into a viral transport medium. The Veterinary Investigation Centre in Norwich confirmed the case as orf and it took weeks to heal. I have always taken the zoonotic aspects of this disease very seriously ever since. When I got a pustule on my finger from my own sheep, I took potentiated sulphonamides by mouth and it healed within three weeks. I always advise clients to wear rubber gloves when dealing with the disease. I also advise any affected people to go to their GP, but not to let the doctor lance the lesion. Virus Orf, which should be called contagious pustular dermatitis, is not a pox virus but a Parapoxvirus. It is allied to viral diseases in cattle, pseudocowpox (caused by the most common virus found on the bovine udder) and bovine papular stomatitis (the oral form of pseudocowpox occurring in young cattle). Both these cattle viruses are self-limiting, rarely causing problems. Sheeppox, which is a Capripoxvirus, is not found in the UK or western Europe. However, it seems to have spread from the Middle East to Hungary.
    [Show full text]
  • Detection of Influenza a Viruses from Environmental Lake and Pond Ice
    TITLE “DETECTION OF INFLUENZA A VIRUSES FROM ENVIRONMENTAL LAKE AND POND ICE” Zeynep A. Koçer A Dissertation Submitted to the Graduate College of Bowling Green State University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY August 2010 Committee: Scott O. Rogers, Advisor W. Robert Midden Graduate Faculty Representative John Castello George Bullerjahn Paul Morris ii ABSTRACT Scott O. Rogers, Advisor Environmental ice is an ideal matrix for the long-term protection of organisms due to the limitation of degradative processes. As a result of global climate change, some glaciers and polar ice fields are melting at rapid rates. This process releases viable microorganisms that have been embedded in the ice, sometimes for millions of years. We propose that viral pathogens have adapted to being entrapped in ice, such that they are capable of infecting naïve hosts after melting from the ice. Temporal gene flow, which has been termed genome recycling (Rogers et al., 2004), may allow pathogens to infect large host populations rapidly. Accordingly, we hypothesize that viable influenza A virions are preserved in lake and pond ice. Our main objective was to identify influenza A (H1-H16) from the ice of a few lakes and ponds in Ohio that have high numbers of migratory and local waterfowl visiting the sites. We developed a set of hemagglutinin subtype-specific primers for use in four multiplex RT-PCR reactions. Model studies were developed by seeding environmental lake water samples in vitro with influenza A viruses and subjecting the seeded water to five freeze-thaw cycles at -20oC and -80oC.
    [Show full text]